Impact of gemcitabine and INC280 combination therapy in advanced tumour stages. A) In the subcutaneous syngeneic mouse model, treatment with gemcitabine was initiated when tumours reached a size of 80–100 mm3 (green line). INC280 treatment was started when tumour size exceeded 300 mm3 (red line). Gemcitabine alone led to a delay in tumour growth; Combination of gemcitabine with cMET inhibition significantly improved tumour growth inhibition. B) In the orthotopic syngeneic tumour model, survival of mice was significantly prolonged with gemcitabine therapy alone (#P < 0.05 vs. control and vs. INC280). A significant survival improvement was observed when gemcitabine was combined with cMET inhibition (*P < 0.001 vs. control and P < 0.05 vs. gemcitabine).